Immunosenescence in lung cancer: Linking aging, chronic inflammation, and tumor immune dysfunction

Lung cancer is predominantly diagnosed in older adults, raising important questions regarding the contribution of age-related biological changes to tumor development and immune regulation. Aging is accompanied by progressive remodeling of the immune and pulmonary systems, including immunosenescence, cellular senescence, inflammaging, metabolic alterations, and changes in tissue homeostasis. However, the extent to which these interconnected processes contribute to impaired antitumor immunity and shape the tumor microenvironment remains incompletely understood. In particular, chronological age does not necessarily reflect the functional state of antitumor immunity, and the biological basis for heterogeneity in immune function and immunotherapy response among older individuals requires further clarification. This issue has become increasingly relevant with the expanding use of immune checkpoint inhibitors in lung cancer and growing interest in biological and immunological measures of aging. In this narrative review, the age-associated remodeling of the pulmonary and immune systems is examined through an integrated perspective linking immunosenescence, cellular senescence, and inflammaging to tumor immune dysfunction. Age-related alterations in T cells, natural killer cells, antigen-presenting cells, macrophages, and the senescent-cell secretory environment are considered in relation to impaired immune surveillance, chronic inflammation, immune escape, and therapeutic response. Emerging approaches targeting senescent cells, metabolic and mitochondrial dysfunction, the aging tumor microenvironment, and immune-cell function are also discussed. By integrating these interconnected dimensions of immune aging, this review provides a framework for understanding why chronological age alone may be insufficient to characterize antitumor immune competence and highlights the potential value of biologically informed approaches to cancer prevention and treatment. This perspective may help guide future research toward more precise assessment of immune aging and individualized therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Journal of Current Biomedical Reports
Published
2026-11-01
DOI
https://doi.org/10.66224/jcbior.7.3.380
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immunosenescence in lung cancer: Linking aging, chronic inflammation, and tumor immune dysfunction

Maryam Falahatzadeh, Mohsen Farrokhpour, Maryam Alsadat Baniaghil, Niloofar Keikhaei et al.
Journal of Current Biomedical Reports
Cancer Immunotherapy and Biomarkers
article

Immunosenescence in lung cancer: Linking aging, chronic inflammation, and tumor immune dysfunction

Maryam Falahatzadeh, Mohsen Farrokhpour, Maryam Alsadat Baniaghil, Niloofar Keikhaei, Seyedeh Hatameh Asadinejad Tahergourabi, Hamed Hekmat Nejad
article en

Abstract

Lung cancer is predominantly diagnosed in older adults, raising important questions regarding the contribution of age-related biological changes to tumor development and immune regulation. Aging is accompanied by progressive remodeling of the immune and pulmonary systems, including immunosenescence, cellular senescence, inflammaging, metabolic alterations, and changes in tissue homeostasis. However, the extent to which these interconnected processes contribute to impaired antitumor immunity and shape the tumor microenvironment remains incompletely understood. In particular, chronological age does not necessarily reflect the functional state of antitumor immunity, and the biological basis for heterogeneity in immune function and immunotherapy response among older individuals requires further clarification. This issue has become increasingly relevant with the expanding use of immune checkpoint inhibitors in lung cancer and growing interest in biological and immunological measures of aging. In this narrative review, the age-associated remodeling of the pulmonary and immune systems is examined through an integrated perspective linking immunosenescence, cellular senescence, and inflammaging to tumor immune dysfunction. Age-related alterations in T cells, natural killer cells, antigen-presenting cells, macrophages, and the senescent-cell secretory environment are considered in relation to impaired immune surveillance, chronic inflammation, immune escape, and therapeutic response. Emerging approaches targeting senescent cells, metabolic and mitochondrial dysfunction, the aging tumor microenvironment, and immune-cell function are also discussed. By integrating these interconnected dimensions of immune aging, this review provides a framework for understanding why chronological age alone may be insufficient to characterize antitumor immune competence and highlights the potential value of biologically informed approaches to cancer prevention and treatment. This perspective may help guide future research toward more precise assessment of immune aging and individualized therapeutic strategies.

Journal of Current Biomedical Reports
Iran University of Medical Sciences (IR), Shiraz University (IR), Shiraz University of Medical Sciences (IR), Firoozgar General Hospital (IR), Golestan University of Medical Sciences (IR), Qom University of Medical Science and Health Services (IR)
Openalex Percentile: Top 16%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon